←Back to Expert Scholars
Translational Medicine / 转化医学ADC Lineage Targets
Shanu Modi
MD
🏢Memorial Sloan Kettering Cancer Center🌐USA
Medical Oncologist
60
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Shanu Modi led the DESTINY-Breast04 trial that established trastuzumab deruxtecan for HER2 low breast cancer, transforming the definition of HER2 targetable disease. She continues to advance ADC combinations and strategies to overcome resistance. Her work defined new lineage based ADC paradigms.
Share:
🧪Research Fields 研究领域
antibody drug conjugates
HER2
breast cancer
trastuzumab deruxtecan
clinical trials
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Shanu Modi 的研究动态
Follow Shanu Modi's research updates
留下邮箱，当我们发布与 Shanu Modi（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment